ImmuONE
- Company typePrivate
- Founded2019
- HeadquartersHatfield, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
ImmuONE firmographics
Firmographics- Name
- ImmuONE
- Legal name
- ImmuONE Ltd.
- Website
- https://immuone.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ImmuONE industry classification
Industry- Product category
- Inhalation Toxicology Contract Research Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Immunotoxicology & Immunogenicity Assessment (HLAGAFAH)
Keywords
Where ImmuONE is headquartered
LocationHeadquarters
- HQ city
- Hatfield
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
ImmuONE business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: ImmuONE provides a wide range of in vitro toxicology testing services including inhalation toxicology, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, and drug development support. Services are tailored to client needs with bespoke experimental design.
- Products (ImmuPHAGE™, ImmuLUNG™, LipidONE™): Sale of proprietary cell culture models. ImmuPHAGE is available for purchase as a product. ImmuLUNG is currently available as part of ImmuONE's service packages with standalone product planned.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Service Packages |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
ImmuONE product offering
Product offeringCore offering
ImmuONE develops and sells proprietary 3D immune-competent human lung cell culture models (ImmuPHAGE™, ImmuLUNG™) and provides contract research services for inhalation safety assessment. The company's offerings include in vitro toxicology testing, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, drug development support, and bespoke assay development using high-content imaging techniques, serving pharmaceutical, chemical, consumer products, and agrichemical companies as human-relevant alternatives to animal testing.
Product overview
ImmuONE is a biotech company offering a portfolio of in vitro lung models and testing services focused on inhalation safety assessment. The core products include ImmuPHAGE™ (human alveolar macrophage-like model) and ImmuLUNG™ (3D co-culture combining epithelial cells and macrophages), along with the LipidONE™ assay service. Supporting services span assay development, inflammation and immune response testing, inhalation toxicology, drug discovery, drug development, and animal product-free testing solutions. The company uses advanced high-content imaging techniques including the morph_ONE™ assay to deliver multi-endpoint assessments from its laboratory facilities in Stevenage, UK.
Differentiator
Problem solved
Functional benefit
Brands
- ImmuLUNG™: 3D human lung model combining human alveolar epithelial cells and alveolar macrophage-like cells for inhalation safety assessment
- ImmuPHAGE™
- LipidONE™
- morph_ONE™
- ImmuONE_Discover™
- ImmuONE_EXPLORE™
- ImmuONE_Workshops™
Products and services
- ImmuLUNG™ Patented 3D co-culture model combining human alveolar epithelial cells and alveolar macrophage-like cells, providing immune-competent in vitro human airways models that maintain phenotype, morphology, and function for up to 14 days for inhalation safety assessment and drug testing. Currently available as part of ImmuONE's service packages, with standalone product planned.
- ImmuPHAGE™ Patented human alveolar macrophage-like cell model for assessing immune responses to inhaled substances, characterized for cell structure, viability, phagocytic activity, and cytokine response. Available for direct purchase or for use within ImmuONE's contract research services.
- LipidONE™ High-content imaging project using HCIA to characterise macrophage health, morphology, and lipid profiles, supporting safety assessment for macrophage responses where lipid accumulation is a concern, including phospholipidosis, autophagy, and atherosclerosis.
- morph_ONE™ Assay Multiparametric high-content imaging analysis tool that tracks subtle morphological shifts in macrophages by combining detailed cell morphology with cell health and biochemical readouts to classify macrophage responses and support safety assessment for foamy macrophages.
- Inflammation and Immune Response Services Comprehensive in vitro alveolar macrophage assays evaluating cytokine activity, macrophage polarisation, phagocytic activity, and inflammatory responses for airways safety assessment. Designed for pharmaceutical and chemical companies requiring mechanistic immune response data on inhaled substances.
- Inhalation Toxicology Services Preclinical in vitro testing services for inhaled product safety, including macrophage toxicology, epithelial toxicology, TEER measurements, LDH assays, and histological analysis. Delivered by ImmuONE's laboratory team in Stevenage.
- Animal Product-Free Services Services adapted to be free of animal-derived products, particularly fetal bovine serum (FBS), replacing with chemically defined media for improved reproducibility and human relevance, aligned with regulatory trends toward animal-free testing.
- Drug Discovery Services Drug screening services assessing toxicity, safety, and inflammatory responses in airways using ImmuPHAGE™ and ImmuLUNG™ models with cell painting assays to support early-stage candidate selection.
- Drug Development Services Expert assistance in understanding inhaled biopharmaceutics from aerosolisation to deposition, including pharmacokinetic and pharmacodynamic assay support for inhaled therapeutics development.
- Assay Development Services On-demand cell assay development tailored to unique toxicity testing needs including high-content image analysis, image flow cytometry, flow cytometry, and immune-competent 3D models, delivered as bespoke consulting engagements.
Quantifiable outcome
- Research shows approximately 90% of drugs shown safe in animals do not work as planned in humans, indicating the critical need for human-relevant testing models
- +1 more outcomes
Companies that use ImmuONE
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
ImmuONE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
ImmuONE partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- FinnAdvancecoreOrgan-on-a-chip company collaboration to test ImmuLUNG™ on AKITA® organ-on-a-chip platform under static and dynamic conditions, presented at MPS World Summit 2023.
- NC3RscoreCRACK IT Challenge consortium working to establish and develop in vitro OECD test guidelines free from animal-derived products, improving human relevance and reproducibility.
- UnilevercoreSponsor of NC3Rs CRACK IT Challenge Phase 2 supporting development of animal-product-free test guidelines.
- AstraZenecacoreSponsor of NC3Rs CRACK IT Challenge Phase 2 supporting development of animal-product-free test guidelines.
- PAN BiotechminorPart of multi-disciplinary consortium for CRACK IT Challenge focused on serum replacement and in vitro innovations.
- University of OxfordminorAcademic partner in consortium for CRACK IT Challenge contributing expertise in pre-clinical assessment.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
ImmuONE competitors and assessment
Company assessmentBroad incumbents
- Emulate Inc: US organ-on-chip company with the Emulate Liver-Chip, Lung-Chip, and other organ platforms used in preclinical drug development. Broad incumbent in the organ-on-chip category, with greater funding scale and broader portfolio than ImmuONE, competing for the same NAMs-driven CRO wallet.
- Cyprotex (Evotec): UK-based preclinical CRO (acquired by Evotec) specializing in in vitro ADME-Tox and safety assessment services for pharmaceutical clients. Broad incumbent in the in vitro preclinical space, with overlapping toxicology service offerings and similar UK positioning.
- Labcorp Drug Development (Covance): Global CRO offering inhalation toxicology, safety assessment, and clinical/preclinical drug development services. Broad incumbent with deep pharma client relationships, posing competitive risk to ImmuONE's contract research services revenue.
- Charles River Laboratories: Global preclinical CRO providing inhalation toxicology, safety assessment, and drug development services to pharmaceutical and chemical clients. Broad incumbent whose scale and established client relationships could absorb or replicate ImmuONE's specialist offering.
Emerging players
- Kirkstall: UK-based organ-on-chip company with the Quasi Vivo multi-organ platform, including lung modules for inhalation toxicology. Emerging peer based in the same UK biotech cluster with comparable preclinical in vitro technology focus.
- MIMETAS: Dutch organ-on-chip company developing the OrganoPlate platform for disease modeling and toxicology, including inflammatory and respiratory applications. Emerging peer with partial overlap in in vitro NAMs for pharmaceutical R&D.
Direct peers
- InSphero: Swiss 3D in vitro microtissue technology company providing organotypic models for drug safety and efficacy testing. Direct peer in 3D human-relevant preclinical models with comparable CRO services and pharmaceutical customer focus.
- Epithelix: Swiss-based developer of 3D in vitro human airway models (MucilAir, SmallAir) used for respiratory toxicology and drug efficacy testing. Direct competitor to ImmuONE in the immune-competent in vitro airway safety assessment space, serving similar pharmaceutical and chemical clients.
- CN Bio Innovations: UK organ-on-chip company developing microphysiological systems including lung and liver models for preclinical drug development. Direct peer in the human-relevant in vitro inhalation/toxicology space, with overlapping pharma customer base and similar regulatory NAMs positioning.
- MatTek (EpiAirway): US-based developer of 3D in vitro human airway epithelial tissue models (EpiAirway) for toxicology, drug delivery, and disease research. Direct peer in reconstructed human airway models for inhalation safety testing, serving overlapping pharmaceutical and consumer products customers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ImmuONE social profiles
Digital presenceImmuONE financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmuONE leadership team
Management profileNumber of profiles
Profiles15 records
ImmuONE funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmuONE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmuONE
What does ImmuONE do?
ImmuONE develops and sells proprietary 3D immune-competent human lung cell culture models (ImmuPHAGE™, ImmuLUNG™) and provides contract research services for inhalation safety assessment. The company's offerings include in vitro toxicology testing, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, drug development support, and bespoke assay development using high-content imaging techniques, serving pharmaceutical, chemical, consumer products, and agrichemical companies as human-relevant alternatives to animal testing.
Is ImmuONE a public or private company?
ImmuONE is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmuONE founded?
ImmuONE was founded in 2019. It employs 11 to 50 people.
Where is ImmuONE based?
ImmuONE is headquartered in Hatfield, United Kingdom, in the Europe region.
How does ImmuONE make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are products (ImmuPHAGE™, ImmuLUNG™, LipidONE™).
Who are ImmuONE's main competitors?
Broad incumbents on record are Emulate Inc, Cyprotex (Evotec), Labcorp Drug Development (Covance) and Charles River Laboratories. Emerging players are Kirkstall and MIMETAS. Direct peers are InSphero, Epithelix, CN Bio Innovations and MatTek (EpiAirway).
Does ImmuONE have an API?
No public API is recorded for ImmuONE.
What industry is ImmuONE in?
ImmuONE's product category is Inhalation Toxicology Contract Research Services. Its primary akta.pro industry code is HLAGAFAH, Immunotoxicology & Immunogenicity Assessment. Its NAICS code is 621511 and its SIC code is 8071.